Abstract
Introduction
In the present study, we examined the levels of the pro-inflammatory cytokine IL-18 and its natural inhibitor, the IL-18 binding protein (IL-18BP), in sera of Wegener’s granulomatosis (WG) patients at various stages of the disease.
Patients and Methods
Sera from eight consecutive biopsy-proven systemic WG patients (four men and four women; age at diagnosis 58.4 ± 13.8 years) were obtained longitudinally with a follow-up period of 55.2 ± 30 months. Sera obtained from 50 healthy subjects were used as controls.
Results and Discussion
Serum levels of IL-18, IL-18BP, and free IL-18 obtained during an active phase of the disease (Birmingham Vasculitis Activity Score, BVAS > 10) were more than twofold higher than levels in the same patients during inactive disease stages (BVAS < 5; P < 0.002; P < 0.006, and P < 0.03 for IL-18, IL-18BP, and free IL-18, respectively). During inactive stages, the levels of these markers were comparable to those of healthy controls. The elevated levels of IL-18 and IL-18BP in sera during active stages of disease suggest a possible role in the pathogenesis and course of the WG.
Conclusion
Despite the elevated IL-18BP levels during active disease, free IL-18 remained higher than in the inactive disease stages, suggesting a potential benefit of administration of exogenous IL-18BP as a novel therapeutic approach for active WG.
References
Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488–98.
Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA. The epidemiology of Wegener’s granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 1996;39:87–92. doi:10.1002/art.1780390112.
Stone JH. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum 2003;48:2299–309. doi:10.1002/art.11075.
Wung PK, Stone JH. Therapeutics of Wegener’s granulomatosis. Nat Clin Pract Rheumatol 2006;2:192–200. doi:10.1038/ncprheum0139.
Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, et al. Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000;43:2025–33. doi:10.1002/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O.
Komocsi A, Lamprecht P, Csernok E, Mueller A, Holl-Ulrich K, Seitzer U, et al. Peripheral blood and granuloma CD4(+)CD28(−) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener’s granulomatosis. Am J Pathol 2002;160:1717–24.
Csernok E, Trabandt A, Muller A, Wang GC, Moosig F, Paulsen J, et al. Cytokine profiles in Wegener’s granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999;42:742–50. doi:10.1002/1529-0131(199904)42:4<742::AID-ANR18>3.0.CO;2-I.
Ludviksson BR, Sneller MC, Chua KS, Talar-Williams C, Langford CA, Ehrhardt RO, et al. Active Wegener’s granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998;160:3602–9.
Torheim EA, Yndestad A, Bjerkeli V, Halvorsen B, Aukrust P, Froland SS. Increased expression of chemokines in patients with Wegener’s granulomatosis—modulating effects of methylprednisolone in vitro. Clin Exp Immunol 2005;140:376–83. doi:10.1111/j.1365-2249.2005.02770.x.
Mukhtyar C, Luqmani R. Current state of tumour necrosis factor {alpha} blockade in Wegener’s granulomatosis. Ann Rheum Dis 2005;64(Suppl 4):iv31–6. doi:10.1136/ard.2005.042416.
Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995;378:88–91. doi:10.1038/378088a0.
Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998;70:281–312. doi:10.1016/S0065-2776(08)60389-2.
Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003;73:213–24. doi:10.1189/jlb.0602313.
Nakamura K, Okamura H, Wada M, Nagata K, Tamura T. Endotoxin-induced serum factor that stimulates gamma interferon production. Infect Immun 1989;57:590–5.
Maxwell JR, Yadav R, Rossi RJ, Ruby CE, Weinberg AD, Aguila HL, et al. IL-18 bridges innate and adaptive immunity through IFN-gamma and the CD134 pathway. J Immunol 2006;177:234–45.
Torigoe K, Ushio S, Okura T, Kobayashi S, Taniai M, Kunikata T, et al. Purification and characterization of the human interleukin-18 receptor. J Biol Chem 1997;272:25737–42. doi:10.1074/jbc.272.41.25737.
Born TL, Thomassen E, Bird TA, Sims JE. Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J Biol Chem 1998;273:29445–50. doi:10.1074/jbc.273.45.29445.
Boraschi D, Dinarello CA. IL-18 in autoimmunity. Eur Cytokine Netw 2006;17:224–52.
Wong CK, Li EK, Ho CY, Lam CW. Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2000;39:1078–81. doi:10.1093/rheumatology/39.10.1078.
Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999;10:127–36. doi:10.1016/S1074-7613(00)80013-8.
Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Novick D, Rubinstein M, et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A 2000;97:1190–5. doi:10.1073/pnas.97.3.1190.
Hurgin V, Novick D, Rubinstein M. The promoter of IL-18 binding protein: activation by an IFN-gamma -induced complex of IFN regulatory factor 1 and CCAAT/enhancer binding protein beta. Proc Natl Acad Sci U S A 2002;99:16957–62. doi:10.1073/pnas.262663399.
Novick D, Schwartsburd B, Pinkus R, Suissa D, Belzer I, Sthoeger Z, et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 2001;14:334–42. doi:10.1006/cyto.2001.0914.
Ludwiczek O, Kaser A, Novick D, Dinarello CA, Rubinstein M, Tilg H. Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn’s disease. Eur Cytokine Netw 2005;16:27–33.
Kaser A, Novick D, Rubinstein M, Siegmund B, Enrich B, Koch RO, et al. Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients. Clin Exp Immunol 2002;129:332–8. doi:10.1046/j.1365-2249.2002.01911.x.
Leach ST, Messina I, Lemberg DA, Novick D, Rubenstein M, Day AS. Local and systemic interleukin-18 and interleukin-18-binding protein in children with inflammatory bowel disease. Inflamm Bowel Dis 2008;14:68–74. doi:10.1002/ibd.20272.
Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 1990;33:1101–7.
Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187–92. doi:10.1002/art.1780370206.
Luqmani RA, Bacon PA, Beaman M, Scott DG, Emery P, Lee SJ, et al. Classical versus non-renal Wegener’s granulomatosis. Q J Med 1994;87:671–8.
Gatto-Menking DL, Yu H, Bruno JG, Goode MT, Miller M, Zulich AW. Sensitive detection of biotoxoids and bacterial spores using an immunomagnetic electrochemiluminescence sensor. Biosens Bioelectron 1995;10:501–7. doi:10.1016/0956-5663(95)96925-O.
Puren AJ, Fantuzzi G, Gu Y, Su MS, Dinarello CA. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 1998;101:711–21. doi:10.1172/JCI1379.
Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al. A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001;44:912–20. doi:10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5.
Khan AM, Elahi F, Hashmi SR, Mahida KH, Ingrams DR. Wegener’s granulomatosis: a rare, chronic and multisystem disease. Surgeon 2006;4:45–52.
Lamprecht P, Kumanovics G, Mueller A, Csernok E, Komocsi A, Trabandt A, et al. Elevated monocytic IL-12 and TNF-alpha production in Wegener’s granulomatosis is normalized by cyclophosphamide and corticosteroid therapy. Clin Exp Immunol 2002;128:181–6. doi:10.1046/j.1365-2249.2002.01801.x.
Jonasdottir O, Petersen J, Bendtzen K. Tumour necrosis factor-alpha (TNF), lymphotoxin and TNF receptor levels in serum from patients with Wegener’s granulomatosis. APMIS 2001;109:781–6. doi:10.1034/j.1600-0463.2001.d01-146.x.
Hewins P, Morgan MD, Holden N, Neil D, Williams JM, Savage CO, et al. IL-18 is upregulated in the kidney and primes neutrophil responsiveness in ANCA-associated vasculitis. Kidney Int 2006;69:605–15. doi:10.1038/sj.ki.5000167.
Hultgren O, Andersson B, Hahn-Zoric M, Almroth G. Serum concentration of interleukin-18 is up-regulated in patients with ANCA-associated vasculitis. Autoimmunity 2007;40:529–31. doi:10.1080/08916930701622783.
Plater-Zyberk C, Joosten LA, Helsen MM, Sattonnet-Roche P, Siegfried C, Alouani S, et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 2001;108:1825–32.
Tissi L, McRae B, Ghayur T, von Hunolstein C, Orefici G, Bistoni F, et al. Role of interleukin-18 in experimental group B streptococcal arthritis. Arthritis Rheum 2004;50:2005–13. doi:10.1002/art.20014.
Jander S, Stoll G. Increased serum levels of the interferon-gamma-inducing cytokine interleukin-18 in myasthenia gravis. Neurology 2002;59:287–9.
Lettesjo H, Hansson T, Bergqvist A, Gronlund J, Dannaeus A. Enhanced interleukin-18 levels in the peripheral blood of children with coeliac disease. Clin Exp Immunol 2005;139:138–43. doi:10.1111/j.1365-2249.2005.02661.x.
Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNF alpha. Immunity 2005;22:131–42.
Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis 2006;65(Suppl 3):iii61–4. doi:10.1136/ard.2006.058511.
Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA, Kim SH. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci U S A 2006;103:3316–21. doi:10.1073/pnas.0511206103.
Lamprecht P, Till A, Steinmann J, Aries PM, Gross WL. Current state of biologicals in the management of systemic vasculitis. Ann N Y Acad Sci 2007;1110:261–70. doi:10.1196/annals.1423.028.
Shoda H, Fujio K, Yamaguchi Y, Okamoto A, Sawada T, Kochi Y, et al. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther 2006;8:R166. doi:10.1186/ar2074.
Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci U S A 2005;102:16309–14. doi:10.1073/pnas.0508237102.
Paulukat J, Bosmann M, Nold M, Garkisch S, Kampfer H, Frank S, et al. Expression and release of IL-18 binding protein in response to IFN-gamma. J Immunol 2001;167:7038–43.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Novick, D., Elbirt, D., Dinarello, C.A. et al. Interleukin-18 Binding Protein in the Sera of Patients with Wegener’s Granulomatosis. J Clin Immunol 29, 38–45 (2009). https://doi.org/10.1007/s10875-008-9217-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-008-9217-0